Opinions of Oral Versus Injectable HIV PrEP in a Racially Diverse Cohort
Concerns of injectable HIV PrEP safety and efficacy demonstrate a need for health care providers to share reliable information with at-risk populations.
Has HIV PrEP Uptake Increased Among High-Risk Persons?
Although HIV PrEP uptake is gradually increasing, usage remains low among key at-risk populations.
Indicators of Severe Outcomes in Chronic Hepatitis B Patients
What are the characteristics and demographics of the chronic hepatitis B patients who develop severe outcomes?
Best of IDWeek 2022
Experts discuss a range of the most topical infectious disease research, presented at the recent IDWeek 2022 conference.
Health Equity and Vaccines: A Combination of Internal and External Forces Drove Low Rates
In communities of color, hesitancy, mistrust, and access issues all drove low COVID-19 vaccination rates during the pandemic.
Hepatitis C Can Be Cured in Young People Who Inject Drugs
Previously thought to be difficult or impossible, one study found HCV and drug use can be treated concurrently in young adults.
Presenting a Range of HIV PrEP Options Encourages Uptake
How do we increase HIV PrEP uptake? “I think the biggest takeaway here is that people need options,” said Travis Sanchez, DVM, MPH.
Bridging the Gap: Finding Treatments for Moderate COVID-19 Disease
Is it safe and beneficial to administer a second immunomodulator in patients with moderate COVID-19? How do we identify which patients are likely to progress to severe disease?
Highlighting IDWeek Abstracts With Thomas Lodise, PharmD, PhD
Lodise breaks down significant findings from his 8 IDWeek 2022 posters.
Analyzing Remdesivir Resistance, 2 Years and Many Variants Later
Remdesivir was the first FDA-approved drug to fight COVID-19, but how has it held up against the latest variants?
Developing a System to Distinguish C Diff Colonization from Infection Within a Health System
Northwestern Medicine developed a testing strategy using a two-step algorithm to improve diagnostic accuracy and treatment outcomes.
Bolstering Influenza Vaccination in People With HIV During COVID-19
One HIV clinical care program in Delaware looked into strategies to increase immunization rates to decrease severe disease as well as minimize hospital capacity.
“Power in the Hands of Patients”: Creating an Accessible Monkeypox Diagnostic
It’s not enough to have accurate infectious disease diagnostics, they must be accessible to the patients most affected.
Taking the Guesswork out of ICU Pneumonia Diagnosis
Encouraging ICU physicians to utilize rapid diagnostics, like the FilmArray Pneumonia Panel, may improve patient outcomes.
Cefepime-Taniborbactam Beats Meropenem for Treating cUTI in Phase 3 Trial
Venatorx Pharmaceuticals is advancing the fight against difficult-to-treat, drug-resistant, gram-negative bacteria with a successful phase 3 clinical trial of its investigational antibiotic cefepime-taniborbactam.
A Rapid Sepsis Diagnostic Test for Better Patient Outcomes
Sepsis diagnosis often takes days. Dr. Roy Davis and his team have developed a test that can diagnose sepsis in an hour.
Assessing Antimicrobial Prescribing for FEP-Susceptible ESBL-E BSIs
A multicenter, retrospective observational study looked at appropriate antibiotics for the treatment in this patient population.
Evaluating the Safety in Hepatitis B Vaccines
Investigators examined the profiles of the HepB-CPG vaccine and HepB-alum vaccines to study the onset of select immune-mediated diseases, herpes zoster, or anaphylaxis.
Utilizing Rapid Diagnostics and DRIP Scores Together to Tailor Therapy and Enhance Stewardship
Using the DRIP Score along with newer diagnostic technology may determine the course of antibiotics for certain patients with pneumonia more efficiently and efficaciously.
Building Momentum for the Pasteur Act
A member of the Infectious Diseases Society of America (IDSA) leadership feels there is some inroads being made in Congress for this antimicrobial resistance legislation.
Adjuvanted Novavax Booster Adapts to New Variants
What makes Novavax’s COVID-19 booster different? The adjuvanted vaccine “has kept recognizing variants that arise,” says Novavax executive director Germán Áñez, MD.
Reevaluating Susceptibility Breakpoints
After the Clinical and Laboratory Standards Institute (CLSI) revised their clinical breakpoints for susceptibility test results, a laboratory at a major medical center in a large midwest city evaluated enterobacterales as it relates to bloodstream infections (BSI) and piperacillin/tazobactam.
Treating Expecting Mothers With Sotrovimab for COVID-19
Late breaking data was reported utilizing the monoclonal antibody during the era of when Omicron variant was the predominant strain and demonstrated good outcomes and tolerability.
Investigational RSV Vaccine for Seniors Demonstrates Efficacy and Safety
During a late breaking session at ID Week, an investigator presented data on the GSK vaccine that is in development.
Evaluating Cefiderocol for Difficult-to-Treat, Gram-Negative Infections
Dr. Simon Portsmouth elaborates on the potential of Shionogi's cefiderocol, an up-and-coming agent in the fight against antimicrobial resistance.
COVID-19 Viral Load and Clinical Outcomes: Is There a Correlation?
Evidence on this has been conflicting and a poster presented at ID Week offers more insights on this significant topic.
“Diagnostic Stewardship Is Always an Area of Need”
At IDWeek 2022, Erica Stohs, MD, MPH, presented surprising findings about unnecessary antibiotics in a cohort coinfected with COVID-19 and pneumonia.
RSV Vaccine Effective at Preventing Lower Respiratory Tract Infection in Older Adults
The investigational vaccine was effective in reducing both lower respiratory tract and all respiratory tract infections.
AMR: Perils and Progress
After Helen Boucher, MD, gave the Maxwell Finland presentation she spoke of the continuing issues as well as the encouraging aspects that have institutions working on the problem.
Vancomycin Is Out, Ridinilazole Is In? Comparing C Difficile Treatments
There is a significant need for C difficile treatments that don’t destroy the microbiome.
2 Clarke Drive Cranbury, NJ 08512